The negative effect of FAF1 on the NF-κB pathway is a promising therapeutic strategy in human cancers with low FAF1 levels, such as cervical and gastric carcinomas, mantle cell lymphomas, and malignant mesothelioma, which show hyperactive NF-κB activity (Figure 3) [111,112]. The gene discussed is NFKB1; the disease is gastric carcinoma.